Estimated market cap $145.04MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Oct 19, 2026, last close Nov 13, 2026.11.18M shares, shares as of Oct 19, 2026CIK 910329The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
14 buys · 2 sells
$226.3K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Medifast Inc's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Medifast Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
58
42.8% of shares · 14 added
Latest 10-Q
Q3 2026
What changed in Medifast Inc's latest quarterly report, compared with the one before.
Filed Oct 26, 2026 · Quarter ended Sep 30, 2026
AI No AI summary for this 10-Q: management's discussion could not be compared, and the other sections did not change.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: risk factors and legal proceedings.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
58 funds report MED. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 74% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 8.26M reported shares by 11.18M shares, from the company’s SEC filing as of Jul 27, 2026.
113 funds hold the stock.
Q3 2026: 43% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202579%
Q3 202584%
Q4 202574%
Q1 202677%
Q2 202674%
Q3 2026 (so far)43%
Q3 2026. 8 new, 14 added to, 18 trimmed, 64 exited since Q2 2026.
Download CSVEvery fund that holds MED, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Medifast Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
140
—
11.18M
$287.9M
Q3 2013
138
-2
11.95M
$321.3M
Q4 2013
126
-12
11.81M
$309.2M
Q1 2014
129
+3
12.63M
$367.8M
Q2 2014
130
+1
12.69M
$385.7M
Q3 2014
123
-7
10.25M
$336.4M
Q4 2014
123
0
10.28M
$344.7M
Q1 2015
125
+2
10.41M
$312.2M
Q2 2015
127
+2
10.16M
$328.3M
Q3 2015
123
-4
9.37M
$253.0M
Q4 2015
129
+6
9.65M
$293.3M
Q1 2016
131
+2
10.29M
$310.5M
Q2 2016
152
+21
10.21M
$339.5M
Q3 2016
164
+12
10.29M
$388.8M
Q4 2016
163
-1
10.81M
$459.1M
Q1 2017
167
+4
11.08M
$491.6M
Q2 2017
161
-6
10.67M
$442.6M
Q3 2017
168
+7
10.37M
$615.6M
Q4 2017
201
+33
10.54M
$736.1M
Q1 2018
225
+24
10.70M
$999.6M
Q2 2018
258
+33
10.65M
$1.7B
Q3 2018
266
+8
11.14M
$2.5B
Q4 2018
246
-20
11.48M
$1.4B
Q1 2019
246
0
11.99M
$1.5B
Q2 2019
251
+5
11.72M
$1.5B
Q3 2019
239
-12
13.51M
$1.4B
Q4 2019
219
-20
13.50M
$1.5B
Q1 2020
201
-18
12.51M
$780.9M
Q2 2020
224
+23
12.16M
$1.7B
Q3 2020
240
+16
10.06M
$1.7B
Q4 2020
261
+21
10.17M
$2.0B
Q1 2021
278
+17
9.74M
$2.1B
Q2 2021
301
+23
10.01M
$2.8B
Q3 2021
296
-5
10.00M
$1.9B
Q4 2021
297
+1
9.80M
$2.1B
Q1 2022
286
-11
9.94M
$1.7B
Q2 2022
284
-2
9.69M
$1.8B
Q3 2022
264
-20
9.53M
$1.0B
Q4 2022
279
+15
9.40M
$1.1B
Q1 2023
267
-12
10.19M
$1.1B
Q2 2023
236
-31
9.67M
$891.9M
Q3 2023
223
-13
9.49M
$711.4M
Q4 2023
216
-7
10.70M
$723.3M
Q1 2024
186
-30
12.35M
$473.4M
Q2 2024
158
-28
10.45M
$228.1M
Q3 2024
140
-18
9.22M
$176.5M
Q4 2024
129
-11
8.92M
$157.2M
Q1 2025
124
-5
8.24M
$111.1M
Q2 2025
120
-4
8.64M
$121.4M
Q3 2025
123
+3
9.29M
$126.9M
Q4 2025
109
-14
8.09M
$86.7M
Q1 2026
112
+3
8.60M
$87.6M
Q2 2026
113
+1
8.26M
$87.7M
Q3 2026
58
-55
4.79M
$55.3M
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (58470H101). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.